Company intelligence / Profile preview

Regeneration Biomedical, Inc.

Newport Beach, California, United Statesregenerationbiomedical.com ↗
Ownership
Private
Development stage
Other
01

Overview

Phase 1 clinical trial data on the first cohort of Alzheimer's patients showed RB-ADSCs were well tolerated, reduced levels of p-Tau and amyloid-beta at 12 weeks, and improved Mini-Mental State Examination (MMSE) scores in two of three subjects[7]

Therapeutic areas
Neurology
Modalities
Autologous stem cell therapy
Industry
Biotech
02

Drug pipeline

1 asset

RB-ADSC-03

Unknown

Beyond the preview

Go deeper on Regeneration Biomedical, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regeneration Biomedical, Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call